Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Therapy Plus Durvalumab for CTCL
NCT03235869Phase 1Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2018
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in cutaneous T-cell lymphoma (CTCL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Percentage of patients that respond to treatment at 1 year and Percentage of patients that completely respond to treatment at 1 year. Planned start Mar 2018; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03235869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235869.